晚期恶性黑色素瘤的治疗研究现状与进展
Therapy for Advanced Malignant Melanoma: Current Research Status and Progress
DOI: 10.12677/jcpm.2024.32038, PDF,   
作者: 贺蓝鑫：青海大学研究生院，青海 西宁；马金华*：青海大学附属医院肿瘤内科，青海 西宁
关键词: 晚期恶性黑色素瘤；靶向治疗；免疫治疗；化疗；手术治疗；Advanced Malignant Melanoma； Targeted Therapy； Immunotherapy； Chemotherapy； Surgical Treatment
摘要: 作为全球患者人数增长最快的恶性肿瘤之一，恶性黑色素瘤的发病机制尚不清晰，其往往容易发生远处转移、扩散，而治疗晚期恶性黑色素瘤患者的手段有限，预后往往是不理想。近些年，得益于免疫学以及肿瘤生物学等前沿学科的迅速发展，黑色素瘤的治疗进入一个新的阶段，尤其是免疫和靶向治疗这一利器的出现与进展，使晚期黑色素瘤患者的生存率有所上升，但仍需要我们继续探索。本文作者就近年来对该病治疗研究现状与进展作如下综述。
Abstract: As one of the fastest growing malignant tumors in the world, the pathogenesis of malignant melanoma is not clear, and it is often prone to distant metastasis and spread, the means in the treatment of advanced malignant melanoma are limited, the prognosis is often not ideal. In recent years, because of the rapid development of immunology and tumor biology, the treatment of melanoma has entered a new stage, especially the appearance and progress of immunology and targeted therapy, the survival rate of patients with advanced melanoma has increased, but we still need to continue to explore. This article reviews the current status and progress in the treatment of this disease in recent years.
文章引用：贺蓝鑫, 马金华. 晚期恶性黑色素瘤的治疗研究现状与进展[J]. 临床个性化医学, 2024, 3(2): 256-262. https://doi.org/10.12677/jcpm.2024.32038

参考文献

[1] Wu, S. and Singh, R.K. (2011) Resistance to Chemotherapy and Molecularly Targeted Therapies: Rationale for Combination Therapy in Malignant Melanoma. Current Molecular Medicine, 11, 553-563. [Google Scholar] [CrossRef] [PubMed]
[2] Gajdos, C. and McCarter, M.D. (2011) Debulking Surgery in Advanced Melanoma. Expert Review of Anticancer Therapy, 11, 1703-1712. [Google Scholar] [CrossRef] [PubMed]
[3] 刘晓丽, 张三元. 原发性外阴恶性黑色素瘤治疗进展[J]. 中国生育健康杂志, 2021, 32(3): 293-294, 301.
[4] Clemente, N., Ferrara, B., Gigliotti, CL., et al. (2018) Solid Lipid Nanoparticles Carrying Temozolomide for Melanoma Treatment. Preliminary in Vitro and in Vivo Studies. International Journal of Molecular Sciences, 19, Article 255. [Google Scholar] [CrossRef] [PubMed]
[5] 蒲远学. 重组人血管内皮抑素联合化疗对皮肤恶性黑色素瘤患者MVD、VEGF计数的影响[J]. 现代医学与健康研究电子杂志, 2020, 4(11): 20-21.
[6] Latimer, N.R., Abrams, K.R., Amonkar, M.M., et al. (2015) Adjusting for the Confounding Effects of Treatment Switching—The BREAK-3 Trial: Dabrafenib versus Dacarbazine. Oncologist, 20, 798-805. [Google Scholar] [CrossRef] [PubMed]
[7] 田慧, 连斌, 斯璐, 等. 化疗联合PD-1抑制剂在晚期黑色素瘤患者中的疗效和安全性分析[J]. 临床肿瘤学杂志, 2021, 26(9): 816-821.
[8] Middleton, M.R., Grob, J.J., Aaronson, N., et al. (2000) Randomized Phase III Study of Temozolomide versus Dacarbazine in the Treatment of Patients with Advanced Metastatic Malignant Melanoma. Journal of Clinical Oncology, 18, 158-166. [Google Scholar] [CrossRef] 
[9] 辛元春, 董方, 高力英, 等. 鼻腔黏膜恶性黑色素瘤放疗联合免疫及靶向治疗1例并文献复[J]. 甘肃医药, 2023, 42(8): 765-768.
[10] 肖建平, 徐国镇, 姜雪松, 等. 立体定向放射治疗在头颈部肿瘤中的应用[C]//中华医学会, 中华医学会放射肿瘤治疗学分会. 2007第六届全国放射肿瘤学学术年会论文集. 中国医学科学院肿瘤医院中国协和医科大学放疗科, 2007: 8.
[11] 秦岚群, 邹征云. 恶性黑色素瘤化疗研究进展[J]. 实用肿瘤学杂志, 2019, 33(2): 167-172.
[12] Gupta, A., Gomes, F. and Lorigan, P. (2017) The Role for Chemotherapy in the Modern Management of Melanoma. Melanoma Management, 4, 125-136. [Google Scholar] [CrossRef] [PubMed]
[13] 慈沁雨, 毛林, 张燕. 原发性阴道恶性黑色素瘤的诊治进展[J]. 实用妇产科杂志, 2022, 38(11): 844-847.
[14] Cui, C., Zhou, L., Lian, B., et al. (2018) Safety and Efficacy of Apatinib Combined with Temozolomide in Advanced Melanoma Patients after Conventional Treatment Failure. Translational Oncology, 11, 1155-1159. [Google Scholar] [CrossRef] [PubMed]
[15] 邹瀚辉, 李涛. PD-1/PD-L1抑制剂在恶性黑色素瘤(新)辅助治疗中的研究进展[J]. 肿瘤防治研究, 2020, 47(2): 141-146.
[16] Weber, J., Mandala, M., Del Vecchio, M., et al. (2017) Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. The New England Journal of Medicine, 377, 1824-1835. [Google Scholar] [CrossRef] 
[17] Eggermont, A.M.M., Blank, C.U., Mandala, M., et al. (2018) Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. The New England Journal of Medicine, 378, 1789-1801. [Google Scholar] [CrossRef] 
[18] Larkin, J., Chiarion-Sileni, V., Gonzalez, R., et al. (2015) Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. The New England Journal of Medicine, 373, 23-34. [Google Scholar] [CrossRef] 
[19] Wolchok, J.D., Chiarion-Sileni, V., Gonzalez, R., et al. (2017) Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. The New England Journal of Medicine, 377, 1345-1356.
[20] Larkin, J., Chiarion-Sileni, V., Gonzalez, R., et al. (2019) Fiveyear Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. The New England Journal of Medicine, 381, 1535-1546. [Google Scholar] [CrossRef]